Poster zum Thema "Migraine"

Zurück
  • P071
  • ePoster
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline clinical characteristics
  • Laurent Delahaye (Toronto, CA)
  • P072
  • ePoster
Difference in sensitization mechanism across low-frequency episodic, high-frequency episodic, and chronic migraine
  • P073
  • ePoster
Comorbidity rates in a large cohort of patients with migraine – a real-world data analysis
  • P074
  • ePoster
Milk and plasma pharmacokinetics of single-dose atogepant in healthy lactating women
  • P075
  • ePoster
Evidence of visual hyperexcitability during and outside of migraine attacks – a reform functional MRI study
  • P076
  • ePoster
Impact of Atogepant on daily functioning in patients with episodic migraine and chronic migraine: Activity Impairment in Migraine-Diary (AIM-D) Item-Level analysis
  • P077
  • ePoster
The impact of the migraine treatment Botulinum toxin on inflammatory and pain responses: insights from an animal model
  • P078
  • ePoster
Results from the 2nd Italian interim analysis of the PEARL study: concomitant acute medication use Over 12 months of Fremanezumab treatment
  • P079
  • ePoster
Differences in cortical activity in interictal, ictal, and chronic migraine
  • P080
  • ePoster
Decreased intracortical inhibition in patients with hemiplegic migraine – a transcranial magnetic stimulation (TMS) study
  • P081
  • ePoster
Long-term (72-week) improvement in headache frequency, severity, and burden following early headache reduction with eptinezumab for migraine prevention
  • P082
  • ePoster
Impact of Atogepant on achieving complete improvement as early as week 1 based on the Activity impairment in Migraine-Diary (AIM-D) domains: post hoc analysis from the ADVANCE, ELEVATE, and PROGRESS trials
  • P083
  • ePoster
Predictors of sleep quality in patients with chronic migraine – a clinical study from Taiwan
  • P084
  • ePoster
Primary senses and migraine – an observational study
  • P085
  • ePoster
Migraine experiences beyond typical symptoms and interventions
  • P086
  • ePoster
Headache in mediterranean anemias – a comparative study of Albanian patients
  • P087
  • ePoster
Which combination of comorbidity makes migraine treatment impossible? A graphical approach
  • P088
  • ePoster
Which types of headaches in the migraine and tension-type spectrum cannot be diagnosed by ICHD3?
  • P089
  • ePoster
Acute Migraine in CADASIL
  • P090
  • ePoster
Retrospective study in patients with chronic and refractory migraine treated with Eptinezumab
  • P091
  • ePoster
Pattern and adherence to Prophylactic treatment in migraine: a multi-center study in Egypt
  • P166
  • ePoster
Migraine does not rest in the arms of Morpheus – a descriptive analysis of sleep quality
  • P167
  • ePoster
French migraine patients ineligible for or resistant to triptans: a primary care real-world study – France-Mig study
  • P168
  • ePoster
Long-term sustained response of Atogepant in episodic and chronic migraine: an interim analysis of a phase 3, open-label, 156-week safety extension study
  • P169
  • ePoster
Salivary CGRP1/CT ratio and Cytokine profile as potential biomarkers of migraine
  • P170
  • ePoster
Interictal burden before initiating Calcitonin gene-related peptide monoclonal antibody for migraine prevention
  • P171
  • ePoster
Anti-CGRP monoclonal antibodies improve sleep quality in migraine patients – a 1-year, multicenter, longitudinal study
  • P172
  • ePoster
Differences in structural neuroimaging in migraine and healthy controls
  • P173
  • ePoster
Switching between triptans: real-life findings from a headache outpatient clinic
  • P174
  • ePoster
Comparing candesartan and Vitamin E for prophylactic treatment in episodic migraine patients
  • P175
  • ePoster
Impact of neck pain with headache among people with migraine, adjusting for headache frequency – Multicountry results from the chronic migraine epidemiology and outcomes – International cross-sectional study
  • P176
  • ePoster
Tryptophan metabolism in migraine
  • P177
  • ePoster
All-cause and cause-specific mortality in persons with migraine – a Danish nationwide cohort study
  • P178
  • ePoster
Migraine preventive treatment with eptinezumab improved patient-reported outcomes in patients with non-response on frequency of monthly migraine days
  • P179
  • ePoster
Treatment with Zavegepant offers improvements in pain severity over 48-hours when compared with Placebo – post hoc results from a randomized Placebo-controlled trial (BHV3500-301)
  • P180
  • ePoster
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline patient-reported outcomes
  • P181
  • ePoster
Long-term safety and discontinuation for rimegepant versus lasmiditan – a matching-adjusted indirect comparison
  • P182
  • ePoster
Chronic migraine and ergots use cause higher serum pentraxin 3 levels and endothelial dysfunction in migraine
  • P183
  • ePoster
Impact of Fremanezumab cessation and reinitiation in migraine management: PEARL study 4th interim analysis
  • P184
  • ePoster
Physical activity levels analysis in patients with chronic migraine treated with Fremanezumab. Phy-My-Mig Study
  • P185
  • ePoster
Migraine prevalence: findings from the Americas' Migraine Observatory Study (AMIGOS)
  • P186
  • ePoster
Changes in acute migraine medications use after initiating or switching to a migraine preventive medication: 12-month findings from the observational TRIUMPH study
  • P187
  • ePoster
Real-world evidence of adding atogepant to OnabotulinumtoxinA for control of chronic migraine – a retrospective chart review
  • P188
  • ePoster
Real-world treatment patterns of Galcanezumab and traditional oral migraine preventives: 12-month results from the TRIUMPH study
  • P189
  • ePoster
Real-world evaluation of Eptinezumab in Italy: effectiveness, tolerability, and safety in high-frequency and chronic migraine at 12 weeks – the EMBRACE study
  • P190
  • ePoster
A cross-sectional analysis evaluating the humanistic and economic burden of migraine with comorbid depression using the national health and wellness survey
  • P191
  • ePoster
Lasmiditan for migraine. Experience in a headache center in Barcelona
  • P192
  • ePoster
Integrative analysis of omics markers associated with neuronal damage in migraine
  • P193
  • ePoster
Exploring the link between inhibitory cognitive control and sensory sensitivity in migraine – a case-control study
  • P194
  • ePoster
Manual therapy as a prophylactic treatment for migraine. A randomized controlled trial
  • P195
  • ePoster
Switching between Ligand and receptor anti-CGRP antibodies in non-responders
  • P196
  • ePoster
Migraine under treatment: Findings from the Americas' Migraine Observatory Study (AMIGOS)
  • P197
  • ePoster
MultiHEAD – work-focused multidisciplinary headache treatment
  • P198
  • ePoster
Migraine epidemiology in Israel – a retrospective database study
  • P199
  • ePoster
Examining trajectories of functional disability – a post-hoc analysis of Zavegepant
  • P200
  • ePoster
Clinical characteristics and outcomes of status migrainosus in a tertiary hospital
  • P201
  • ePoster
Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like sensitivity without motor impairment in FHM1 and WT mice
  • P202
  • ePoster
Long-term effectiveness of eptinezumab in patients with migraine and 2-4 prior preventive treatment failures who self-reported psychiatric comorbidities at screening
  • P203
  • ePoster
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline migraine treatment patterns
  • P204
  • ePoster
Efficacy of fremanezumab treatment for migraine prevention in patients with migraine and major depressive disorder: results from the open-label extension of the UNITE study
  • P205
  • ePoster
White matter hyperintensities in a Portuguese cohort of migraine patients: prevalence, characterization and clinical correlations
  • P206
  • ePoster
Risk factors for migraine onset – a systematic review and three-level meta-analysis
  • P207
  • ePoster
Long-term outcomes (over 24 months) of anti-CGRP therapy in migraine – a real-world single-center study
  • P208
  • ePoster
Electrophysiological disparities in trigeminal ganglion neurons induced by serotonin depletion: Implications for migraine in rats model
  • P209
  • ePoster
Comparison of brain structural MRI before and after 6-months of preventive treatment with anti-CGRP monoclonal antibodies and onabotulinumtoxinA in people with migraine
  • P210
  • ePoster
Is migraine a severity predictor in CADASIL patients? Early results from CADA-Migraine study
  • P211
  • ePoster
Analysis of serum alpha-CGRP levels in different disorders and its meaning regarding the specificity of increased concentrations of the peptide for chronic migraine
  • P212
  • ePoster
Impact of Atogepant on long-term response rates and migraine-specific quality of life in migraine prevention: interim analysis of a phase 3, multicenter, open-label, 156-week extension study
  • P213
  • ePoster
Psychiatric comorbidities in migraine patients and the influence of monoclonal antibody therapy against CGRP – preliminary results
  • P214
  • ePoster
Psychiatric and sleep disorders in migraine patients: common comorbidities
  • P215
  • ePoster
Cortical spreading depolarization-evoked cortical inflammation correlates with activation of meningeal macrophages
  • P216
  • ePoster
Preliminary results utilizing the Ussing Chamber to investigate meningeal properties
  • P217
  • ePoster
Reliability and validity of Turkish version of migraine specific quality of life v2.1 questionnaire
  • P218
  • ePoster
Influence of precipitants on the characteristics of Chronic migraine study. Study in a series of 1584 patient
  • P219
  • ePoster
MIGARGILE tool: How can it help for patient with migraine recruitment in randomized clinical trial?
  • P220
  • ePoster
Structural connectivity changes in migraine involving the cerebellum
  • P221
  • ePoster
Effectiveness of laser acupuncture for anxiety and depression among patients with chronic migraine – propensity score matching study
  • P222
  • ePoster
Telemedicine suitability prediction in migraine care – a machine learning approach
  • P223
  • ePoster
Phenotyping interictal migraine patients according to clinical and psychophysical characteristics
  • P224
  • ePoster
Cabergoline as a preventive migraine treatment – a randomized clinical pilot trial
  • P225
  • ePoster
The RELEASE umbrella study: An international, non-interventional, prospective cohort study assessing the effectiveness of Eptinezumab in patients initiating preventive treatment for migraine
  • P226
  • ePoster
Effect of testosterone therapy on migraine in a patient with congenital bilateral anorchia
  • P227
  • ePoster
Migraine is associated with a significantly increased risk for breast cancer – data of more than 1.5 million women
  • P228
  • ePoster
Perspectives and expectations of chronic migraine patients receiving and not receiving OnabotulinumtoxinA on physiotherapy and rehabilitation treatment
  • P229
  • ePoster
Utilization of healthcare resources and sick leave in a large cohort of migraine patients – a real-world data analysis
  • P230
  • ePoster
Cervical stabilization exercise training via telerehabilitation in individuals with migraine – a randomized controlled trial
  • P231
  • ePoster
Possibilities of mindfulness-based cognitive therapy in the treatment of chronic headaches
  • P314
  • ePoster
Contralateral cranial autonomic symptoms in migraine patients, in Azerbaijani population
  • P315
  • ePoster
A hidden burden – the impact of medication collection in hospital pharmacies in multiple sclerosis and migraine patients
  • P316
  • ePoster
Low-level 810nm laser acupuncture for patients with chronic migraine – a follow-up phase of randomized controlled trial
  • P317
  • ePoster
Relationships between migraine and interoception
  • P318
  • ePoster
Attentional network deficits in migraine patients: neural indicators and implications
  • P319
  • ePoster
Melatonin for migraine prevention – a meta-analysis of efficacy and safety
  • P320
  • ePoster
Transcranial Doppler in migraine
  • P321
  • ePoster
Migraine and cognitive dysfunction: a narrative review
  • P322
  • ePoster
Occipital nerve block as a safe and effective treatment for the management of refractory migraine in a pregnant woman
  • P323
  • ePoster
Assessment of Cutaneous Allodynia and its relation to Proinflammatory blood markers in migraine
  • P324
  • ePoster
Understanding the anti-migraine effect of MG25, a novel curcumin derivative through invitro and invivo perspectives
  • P325
  • ePoster
Serum melatonin levels and migraine headache: results from a cross-sectional study in Iran
    • v1.20.0
    • © Conventus Congressmanagement & Marketing GmbH